PeptideDB

JNJ-26990990

CAS No.: 877316-38-6

JNJ-26990990 is a broad-spectrum anticonvulsant drug as a second-generation followup to the marketed drug topiramate. It
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Description JNJ-26990990 is a broad-spectrum anticonvulsant drug as a second-generation followup to the marketed drug topiramate. It was designed to have the same anticonvulsant effects as topiramate, but without the side effects associated with topiramate's carbonic anhydrase inhibition. It also has potential use in the treatment of inflammatory pain, neuropathic pain, and depression. JNJ-26990990 entered phase II clinical trials in October 2007.
molecular weight 242.32
Molecular formula C9H10N2O2S2
CAS 877316-38-6
Storage Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility DMSO: 65 mg/ml (268.24 mM)
References 1. Fiore A D , Simone G D , Alterio V , et al. The anticonvulsant sulfamide JNJ-26990990 and its S,S-dioxide analog strongly inhibit carbonic anhydrases: solution and X-ray crystallographic studies[J]. Organic & Biomolecular Chemistry, 2016, 14(21):4853-4858. 2. Lin R, Weaner LE, Hoerr DC, Salter R, Gong Y. Expeditious syntheses of stable and radioactive isotope-labeled anticonvulsant agent, JNJ-26990990, and its metabolites. J Labelled Comp Radiopharm. 2013 Jan;56(1):22-6. doi: 10.1002/jlcr.301Epub 2013 Jan 10. PubMed PMID: 24285137. 3. Parker MH, Smith-Swintosky VL, McComsey DF, Huang Y, Brenneman D, Klein B, Malatynska E, White HS, Milewski ME, Herb M, Finley MF, Liu Y, Lubin ML, Qin N, Iannucci R, Leclercq L, Cuyckens F, Reitz AB, Maryanoff BE. Novel, broad-spectrum anticonvulsants containing a sulfamide group: advancement of N-((benzo[b]thien-3-yl)methyl)sulfamide (JNJ-26990990) into human clinical studies. J Med Chem. 2009 Dec 10;52(23):7528-36. doi: 10.1021/jm801432r. PubMed PMID: 19388676.